Cynthia X. Ma, MD, PhD, discusses positive interim data from the phase 1 ReDiscover trial in PI3Kα-mutated HR-positive, HER2-negative breast cancer.
Clinical Updates in PIK3CA+ Metastatic Breast Cancer
Experts provide insights on the first-in-human phase 1 ReDiscovertrial trial, evaluating the mutant-selective PI3Kα inhibitor RLY-2608, which is currently enrolling patients.
Sara M. Tolaney, MD, MPH, discusses the ongoing development of mutation-selective PI3K inhibitors in PI3K-mutant metastatic breast cancer.
Komal Jhaveri, MD, FACP, highlights the novel PI3Kα inhibitor RLY-2608 and discusses the details of the first-in-human trial of the agent.
Cristina Saura Manich, MD, PhD, discusses the phase 1 ReDiscover study evaluating RLY-2608 in patients with PIK3CA-mutated advanced breast cancer and other solid tumors.
Komal Jhaveri, MD, FACP, discusses the implications of investigating treatment with RLY-2608 in patients with PIK3CA-mutant advanced ER+ breast cancer.
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
3
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
4
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
5